✦ LIBER ✦

Yttrium 90 ibritumomab tiuxetan (Zevalin®): A new bullet in the fight against malignant lymphoma?

✍ Scribed by Bjoern Chapuy; Karin Hohloch; Lorenz Trümper

Book ID: 112011450
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 204 KB
Volume: 2
Category: Article
ISSN: 1860-6768
DOI: 10.1002/biot.200700043

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Recommendations for the use of Yttrium-9

Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma

✍ Oliver Weigert; Tim Illidge; Wolfgang Hiddemann; Martin Dreyling 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB

P166 Experience with the use of yttrium-

P166 Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

✍ J. Demeter; K. Balassa; M. D¨om¨ot¨or; M. Egyed; Z. Gasztonyi; H. Aryab; M. Gurz 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

cursor was set to the same position in each sample, where 5% of T/NK cells were Zap-70 negative. Zap-70 and CD38 labeling was determined on CD19+ cells. Results: With dichotomized evaluation of CD38 and Zap-70 expression 70% of the cases showed concordant results: 32% were Zap-70+/CD38+ and 38% were

Phase I/II90Y-Zevalin (yttrium-90 ibritu

Phase I/II90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma

✍ Gregory A. Wiseman; Christine A. White; Michael Stabin; William L. Dunn; William 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 166 KB

Yttrium-90 Ibritumomab Tiuxetan as a Sin

Yttrium-90 Ibritumomab Tiuxetan as a Single Agent in Patients With Pretreated B-Cell Lymphoma: Evaluation of the Long-Term Outcome

✍ Pier Luigi Zinzani; Letizia Gandolfi; Vittorio Stefoni; Stefano Fanti; Mariapaol 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 183 KB

A randomized study comparing yttrium-90

A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma

✍ Avichai Shimoni; Irit Avivi; Jacob M. Rowe; Moshe Yeshurun; Itai Levi; Reuven Or 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 278 KB

Antilymphoma Treatments Given Subsequent

Antilymphoma Treatments Given Subsequent to Yttrium 90 Ibritumomab Tiuxetan Are Feasible in Patients with Progressive Non-Hodgkin's Lymphoma: A Review of the Literature

✍ Ansell, Stephen M.; Schilder, Russell J.; Pieslor, Peter C.; Gordon, Leo I.; Emm 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 111 KB